The effect of EPA and DHA on metabolic syndrome patients: A systematic review of randomised controlled trials

British Journal of Nutrition

Volumn 107, Issue SUPPL. 2, 2012, Pages

  Lopez Huertas, Eduardo ^a  

^a CSIC   (Spain)

Author keywords

Cardiovascular disease; Metabolic syndrome; Systematic review; Very long chain n3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; HUMAN; LIPOLYSIS; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 84861143622     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512001572     Document Type: Review

References (77)

1. Expert Panel (2001) Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
2. Zimmet P, Alberti KG, Shaw J, et al. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787. (Pubitemid 34000780)
3. Eckel RH, Grundy SM & Zimmet PZ (2005) The metabolic syndrome. Lancet 365, 1415-1428. (Pubitemid 40523737)
4. Grundy SM, Cleeman JI, Daniels SR, et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112, 2735-2752. (Pubitemid 41532612)
5. Roche HM (2005) Fatty acids and the metabolic syndrome. Proc Nutr Soc 64, 23-29. (Pubitemid 40685748)
6. Melanson EL, Astrup A & Donahoo WT (2009) The relationship between dietary fat and fatty acid intake and body weight, diabetes, and the metabolic syndrome. Ann Nutr Metab 55, 229-243.
7. Warensjo E, Riserus U & Vessby B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48, 1999-2005. (Pubitemid 41416909)
8. Hooper L, Thompson RL, Harrison RA & SummerbellOmega 3 fatty acids for prevention and treatment of cardiovascular disease (Cochrane Review) In: The Cochrane Library, Issue 2. Oxford, update 1 August 2004
9. EFSA (2009) Opinion of the scientific panel on dietetic products, nutrition and allergies on a request from the Commission related to labelling reference intake values for n-3 and n-6 polyunsaturated fatty acids. EFSA J 1176, 1-11.
10. FAO/WHO (2010) The Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition. FAO food and nutrition paper 91. Food and Agriculture Organisation of the United Nations, Rome. ISSN 0254-4725.
11. Kris-Etherton PM, Harris WS, Appel LJ & AHA Nutrition Committee, American Heart Association (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 23, 151-152. (Pubitemid 36231919)
12. Yamada H, Yoshida M, Nakano, et al. (2008) In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 28, 2173-2179.
13. Esposito K, Marfella R, Ciotola M, et al. (2004) Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292, 1440-1446. (Pubitemid 39258336)
14. Shaw DI, Tierney AC, McCarthy S, et al. (2009) LIPGENE food-exchange model for alteration of dietary fat quantity and quality in free-living participants from eight European countries. Br J Nutr 101, 750-759.
15. Brady LM, Williams CM & Lovegrove JA (2004) Dietary PUFA and the metabolic syndrome in Indian Asians living in the UK. Proc Nutr Soc 63, 115-125. (Pubitemid 38543879)
16. Benito P, Caballero J, Moreno J, et al. (2006) Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clin Nutr 25, 581-587. (Pubitemid 44070584)
17. Saito Y, Yokoyama M, Origasa H, JELIS Investigators Japan, et al. (2008) Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200, 135-140.
18. Ebrahimi M, Ghayour-Mobarhan M & Rezaiean S (2009) Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol 64, 321-327.
19. Tulk HM & Robinson LE (2009) Modifying the n-6/n-3 polyunsaturated fatty acid ratio of a high-saturated fat challenge does not acutely attenuate postprandial changes in inflammatory markers in men with metabolic syndrome. Metabolism 58, 1709-1716.
20. Satoh N, Shimatsu A & Kotani K (2009) Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 32, 1004-1008.
21. Montegaard C, Tulk HM & Lauritzen L (2010) Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome. J Nutr 140, 38-43.
22. Hartwich J, Malec MM & Partyka L (2009) The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation-insights from the LIPGENE study. Clin Nutr 28, 510-515.
23. Jiménez-Gómez Y, Marín C, Pérez- Martínez P, et al. (2010) A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. J Nutr 140, 1595-1601.
24. Gulseth HL, Gjelstad IM, Tierney AC, et al. (2010) Dietary fat modifications and blood pressure in subjects with the metabolic syndrome in the LIPGENE dietary intervention study. Br J Nutr 104, 160-163.
25. Simão AN, Godeny P & Lozovoy MA (2010) Effect of n-3 fatty acids in glycemic and lipid profiles, oxidative stress and total antioxidant capacity in patients with the metabolic syndrome. Arq Bras Endocrinol Metabol 54, 463-469.
26. Satoh N, Shimatsu A, Kotani K, et al. (2007) Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 30, 144-146. (Pubitemid 46061295)
27. Tierney AC, McMonagle J, Shaw DI, et al. (2010) Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) (Epublication 12 October 2010 ahead of print version).
28. Petersson H, Risérus U, McMonagle J, et al. (2010) Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study. Br J Nutr 104, 1357-1362.
29. Perez-Martinez P, Moreno-Conde M, Cruz-Teno C, et al. (2010) Dietary fat differentially influences regulatory endothelial function during the postprandial state in patients with metabolic syndrome: from the LIPGENE study. Atherosclerosis 209, 533-538.
30. van Hees AM, Saris WH, Hul GB, et al. (2010) Effects of dietary fat modification on skeletal muscle fatty acid handling in the metabolic syndrome. Int J Obes (Lond) 34, 859-870.
31. Hartwich J, Leszczynska-Golabek I, Kiec-Wilk B, et al. (2010) Lipoprotein profile, plasma ischemia modified albumin and LDL density change in the course of postprandial lipemia. Insights from the LIPGENE study. Scand J Clin Lab Invest 70, 201-208.
32. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P & Lau J (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189, 19-30. (Pubitemid 44468073)
33. Vessby B, Unsitupa M, Hermansen K, et al. (2001) Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 44, 312-319. (Pubitemid 32234457)
34. Masson D, Jiang XC, Lagrost L & Tall AR (2009) The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res, Supp. l, S201-S206.
35. Ministry of Health, Labour and Welfare. The National Nutrition Survey in Japan (2001) Health and Nutrition Information Research Committee, eds. Tokyo, Japan: Daiichi Shuppan; 2003: 83-91.
36. Pockley AG, Georgiades A, Thulin T, et al. (2003) Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 42, 235-238. (Pubitemid 37093466)
37. Ogasawara K, Mashiba S, Wada Y, et al. (2004) A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 174, 349-356. (Pubitemid 38597093)
38. Matsuzawa Y, Funahashi T, Kihara S, et al. (2004) Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24, 29-33. (Pubitemid 38082408)
39. Mansia G, De Backer G, Dominiczak A, et al. (2007) Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25, 1105-1187. (Pubitemid 46924065)
40. Mori TA, Burke V, Puddey IB, et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 1085-1094. (Pubitemid 30230554)
41. Woodman RJ, Mori TA, Burke V, et al. (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76, 1007-1015. (Pubitemid 35244671)
42. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60, 473-485. (Pubitemid 9254048)
43. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, et al. (2005) Clinical relevance of postprandial lipaemia. Curr Med Chem 12, 1931-1945. (Pubitemid 41015175)
44. Ruotolo G & Howard BV (2002) Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4, 494-500.
45. Giugliano D, Ceriello A & Esposito K (2008) Are there specific treatments for the metabolic syndrome? Am J Clin Nutr 87, 8-11.
46. Harris WS (2007) Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res 55, 217-223. (Pubitemid 46518155)
47. The British Nutrition Foundation (1999) n-3 Fatty Acids and Health. Briefing Paper. London: British Nutrition Foundation.
48. Baro L, Fonollá J, Peña JL, et al. (2003) n-3 Fatty acids plus oleic acid and vitamin supplemented milk consumption reduces total and LDL cholesterol, homocysteine and levels of endothelial adhesion molecules in healthy humans. Clin Nutr 22, 175-182. (Pubitemid 36372462)
49. Carrero JJ, Baró L, Fonollá J, et al. (2004) Cardiovascular effects of milk enriched with o-3 polyunsaturated fatty acids, oleic acid, folic acid, and vitamins E and B6 in volunteers with mild hyperlipidemia. Nutrition 20, 521-527. (Pubitemid 38692494)
50. Jacobsen TA (2008) Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 87, 1981S-1990S.
51. Harris WS (1997) n-3 Fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 65, 1645-1654.
52. EFSA Panel on Dietetic Products, Nutrition and Allergies (2009) Scientific Opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal blood pressure (ID 502), maintenance of normal HDL-cholesterol concentrations (ID 515), maintenance of normal (fasting) blood concentrations of triglycerides (ID 517), maintenance of normal LDL-cholesterol concentrations (ID 528, 698) and maintenance of joints (ID 503, 505, 507, 511, 518, 524, 526, 535, 537) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 7, 1263-1289.
53. Austin MA, Breslow JL & Hennekens CH (1988) Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260, 1917-1921.
54. Rizzo M & Berneis K (2006) Low density lipoproteins size and cardiovascular risk assessment. QJM 99, 1-14. (Pubitemid 43124966)
55. Kwiterovich PO Jr (2002) Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 90, 30i-47i. (Pubitemid 35284909)
56. Griffin BA (1999) Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 58, 163-169. (Pubitemid 29225561)
57. Murphy KJ, Meyer BJ, Mori TA, et al. (2007) Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. Br J Nutr 97, 749-757. (Pubitemid 46470684)
58. Mancia G, De Backer G, Dominiczak A, et al. (2007) Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology, 2007. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25, 1105-1187. (Pubitemid 46924065)
59. Kromhout D, Bosschieter EB & de Lezenne Coulander C (1985) The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 312, 1205-1209. (Pubitemid 15009153)
60. Galgani JE, Uauy RD, Aguirre CA, et al. (2008) Effect of the dietary fat quality on insulin sensitivity. Br J Nutr 100, 471-479.
61. Nettleton JA & Katz R (2005) n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 105, 428-440. (Pubitemid 40326734)
62. Friedberg CE, Janssen MJ, Heine RJ, et al. (1998) Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 21, 494-500. (Pubitemid 28172922)
63. Montori VM, Farmer A, Wollan PC, et al. (2000) Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 23, 1407-1415.
64. Hartweg J, Perera R, Montori V, et al. (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev CD003205.
65. Hartweg J, Farmer AJ, Holman RR, et al. (2009) Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol 20, 30-38.
66. Mostad IL, Bjerve KS, Basu S, et al. (2009) Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. Metabolism 58, 1753-1761.
67. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27, 813-823. (Pubitemid 38280558)
68. Basu S (2007) Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med Res Rev 27, 435-468. (Pubitemid 46991953)
69. Basu S (2008) F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 10, 1405-1434.
70. Kris-Etherton PM, Harris WS, Appel LJ & American Heart Association. Nutrition Committee (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 2747-2757. (Pubitemid 35364932)
71. Kromhout D, Feskens EJ & Bowles CH (1995) The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 24, 340-345.
72. Dolecek TA & Granditis G (1991) Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 66, 205-216.
73. Daviglus ML, Stamler J, Orencia AJ, et al. (1997) Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336, 1046-1053. (Pubitemid 27163856)
74. Gorjão R, Azevedo-Martins AK, Rodrigues HG, et al. (2009) Comparative effects of DHA and EPA on cell function. Pharmacol Ther 122, 56-64.
75. Buckley R, Shewring B, Turner R, et al. (2004) Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 92, 477-483. (Pubitemid 40277068)
76. Arterburn LM, Hall EB & Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83, 1467S-1476S. (Pubitemid 44713087)
77. Lopez-Huertas E (2010) Health effects of oleic acid and long chain omega-3 fatty acids (EPA and DHA) enriched milks. A review of intervention studies. Pharmacol Res 61, 200-207.